Assignee
LENNHAM PHARMACEUTICALS INC
US·12 granted patents·12 pending applications·89 citations·filing 2019–2025
Top patents by PatentIndex Score
24 records- 0198US11000534B1Deuterated derivatives of psilocybin and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2020·Granted May 11, 2021·57 cites·12 claims
- 0297US11324762B2Deuterated derivatives of psilocybin and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2021·Granted May 10, 2022·12 cites·14 claims
- 0397US10582716B1Deuterated caffeine and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2019·Granted Mar 10, 2020·7 cites·23 claims
- 0496US11344564B1Method of treatment based on reduced monoamine oxidase a activityLENNHAM PHARMACEUTICALS INC·Filed 2021·Granted May 31, 2022·5 cites·22 claims
- 0594US11547127B2Deuterated caffeine and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2022·Granted Jan 10, 2023·1 cites·20 claims
- 0694US10765130B1Deuterated caffeine and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2020·Granted Sep 8, 2020·3 cites·22 claims
- 0790US11202785B1Deuterated forms of testosterone and methods of useLENNHAM PHARMACEUTICALS INC·Filed 2021·Granted Dec 21, 2021·2 cites·15 claims
- 0888US11666073B2Deuterated caffeine and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2020·Granted Jun 6, 2023·1 cites·22 claims
- 0988US11471469B2Deuterated forms of testosterone and methods of useLENNHAM PHARMACEUTICALS INC·Filed 2021·Granted Oct 18, 2022·1 cites·25 claims
- 1088US2024284942A1Deuterated caffeine and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1185US2023371555A1Deuterated caffeine and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1280US2025248424A1Deuterated caffeine and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1378US2024000815A1Deuterated derivatives of psilocybin and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1477US12090159B2Deuterated forms of testosterone and methods of useLENNHAM PHARMACEUTICALS INC·Filed 2022·Granted Sep 17, 2024·0 cites·20 claims
- 1573US2020390128A1Deuterated caffeine and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1671US11633371B2Deuterated forms of acetaminophen and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 25, 2023·0 cites·28 claims
- 1768US2022110955A1Deuterated derivatives of psilocybin and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1867US2024409405A1Products comprising deuterium-enriched waterLENNHAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1960US12194046B2D9-caffeine compositions and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2021·Granted Jan 14, 2025·0 cites·29 claims
- 2060US2023062523A1Method of treatment based on reduced monoamine oxidase a activityLENNHAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2160US2022313630A1Deuterated forms of acetaminophen and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2257US2023355632A1Deuterated paraxanthine and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2356US2024000799A1Deuterated forms of testosterone and methods of useLENNHAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2450US2021378266A9Deuterated caffeine and uses thereofLENNHAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when LENNHAM PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →